Keeping quiet on clinical trials

Several queries have been raised regarding the precise manner in which Mexico brings protection to one of the elements that involves more effort, time and money in the commercialisation of new chemical and biological molecules with therapeutic application: the invaluable clinical data. For most pharma companies, it is not quite clear how prepared the Mexican Law is to offer data exclusivity.